Curia nets contract for cannabinoid candidate and taps a new president of manufacturing
The CDMO Curia, fresh off an expansion a year ago, is scaling up manufacturing for a candidate from an Australian biotech.
Incannex Healthcare, a biotech centered on producing cannabinoid-based medicines and psychedelic therapies, is using Curia Global to further develop and manufacture a GMP-grade inhaled drug product for the treatment of concussion and traumatic brain injury originally developed by the biotech.
The candidate, dubbed IHL-216A, combines cannabidiol and isoflurane to treat concussions and other traumatic brain injuries. The intent is to improve recovery time and decrease the impact of the injury on the quality of life.
The deal with Curia, for which financial details were not disclosed, will have the company scale up the fill-finish manufacture of IHL-216A in compliance with cGMP. Curia will also generate data on the quality and stability of the candidate to support future regulatory filings.
The first manufactured batch will be used in the Phase I clinical trial, which will commence once feedback on the candidate’s development plan is received from the FDA, which is set to conclude in Q3 2022.
In addition to the deal, Curia has named a new president for its manufacturing operation. The company is tapping Niall Condon, effective immediately, as current president Steve Lichter retires. He’ll be responsible for the delivery of Curia’s commercial manufacturing services and products, including APIs and other drug products.
“The CDMO industry is dynamic, and Curia is uniquely positioned to serve customers with its innovative portfolio of solutions and products spanning R&D through manufacturing. I’m looking forward to meeting its talented community of colleagues and making an impact for our customers and the patients they serve,” Condon said.
Condon has extensive experience in the manufacturing field as he recently served as head of API and OSD manufacturing at Viatris, which was formed through the merger of Mylan and Pfizer’s Upjohn. Before that, he was a senior vice president at Pfizer, where he helped build the Upjohn Division. He also spent over 30 years at Pfizer in roles of increasing responsibility in manufacturing and other operations.